Trichomonas vaginalis: a review of epidemiologic, clinical and treatment issues

Patricia Kissinger, Patricia Kissinger

Abstract

Trichomonas vaginalis (TV) is likely the most common non-viral sexually transmitted infection (STI) in the world. It is as an important source of reproductive morbidity, a facilitator of HIV transmission and acquisition, and thus it is an important public health problem. Despite its importance in human reproductive health and HIV transmission, it is not a reportable disease and surveillance is not generally done. This is problematic since most persons infected with TV are asymptomatic. Metronidazole (MTZ) has been the treatment of choice for women for decades, and single dose has been considered the first line of therapy. However, high rates of retest positive are found among TV infected persons after single dose MTZ treatment. This has not been explained by drug resistance since in vitro resistance is only 2-5 %. Treatment failure can range from 7-10 % and even higher among HIV+ women. Treatment efficacy may be influenced by vaginal ecology. The origins of repeat positives need further explanation and better treatment options are needed.

Figures

Fig. 1
Fig. 1
Possible causes of a repeat TV+ test after treatment among TV infected persons

References

    1. World Health Organization W. Global incidence and prevalence of selected curable sexually transmitted infections. 2008. ISBN 978 92 4 150383 9
    1. World Health O. Global prevalence and incidence of selected curable sexually transmitted infections: overviews and estimates. In: WHO/ HIV_AIDS. Edited by Organization WH. Geneva; 2001.
    1. Miller WC, Swygard H, Hobbs MM, Ford CA, Handcock MS, Morris M, Schmitz JL, Cohen MS, Harris KM, Udry JR. The prevalence of trichomoniasis in young adults in the United States. Sex Transm Dis. 2005;32(10):593–598. doi: 10.1097/.
    1. Sutton M, Sternberg M, Koumans EH, McQuillan G, Berman S, Markowitz L. The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States, 2001–2004. Clin Infect Dis. 2007;45(10):1319–1326. doi: 10.1086/522532.
    1. Gregson S, Mason PR, Garnett GP, Zhuwau T, Nyamukapa CA, Anderson RM, Chandiwana SK. A rural HIV epidemic in Zimbabwe? Findings from a population-based survey. Int J STD AIDS. 2001;12(3):189–196. doi: 10.1258/0956462011917009.
    1. Klinger EV, Kapiga SH, Sam NE, Aboud S, Chen CY, Ballard RC, Larsen U. A Community-based study of risk factors for Trichomonas vaginalis infection among women and their male partners in Moshi urban district, northern Tanzania. Sex Transm Dis. 2006;33(12):712–718. doi: 10.1097/01.olq.0000222667.42207.08.
    1. Mgone CS, Lupiwa T, Yeka W. High prevalence of Neisseria gonorrhoeae and multiple sexually transmitted diseases among rural women in the Eastern Highlands Province of Papua New Guinea, detected by polymerase chain reaction. Sex Transm Dis. 2002;29(12):775–779. doi: 10.1097/00007435-200212000-00007.
    1. Wangnapi RA, Soso S, Unger HW, Sawera C, Ome M, Umbers AJ, Ndrewei N, Siba P, Li Wai Suen CS, Vallely A, et al. Prevalence and risk factors for Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis infection in pregnant women in Papua New Guinea. Sex Transm Infect. 2015;91(3):194–200. doi: 10.1136/sextrans-2014-051670.
    1. Lan PT, Lundborg CS, Phuc HD, Sihavong A, Unemo M, Chuc NT, Khang TH, Mogren I. Reproductive tract infections including sexually transmitted infections: a population-based study of women of reproductive age in a rural district of Vietnam. Sex Transm Infect. 2008;84(2):126–132. doi: 10.1136/sti.2007.027821.
    1. Depuydt CE, Leuridan E, Van Damme P, Bogers J, Vereecken AJ, Donders GG. Epidemiology of Trichomonas vaginalis and human papillomavirus infection detected by real-time PCR in flanders. Gynecol Obstet Invest. 2010;70(4):273–280. doi: 10.1159/000314017.
    1. Huang HC, Yu SF, Cai M, Tan F, Zheng XY, Pan CW. Preparation of monoclonal antibodies against the adhesion protein 33 of Trichomonas vaginalis. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2007;25(2):97–100.
    1. Johnston VJ, Mabey DC. Global epidemiology and control of Trichomonas vaginalis. Curr Opin Infect Dis. 2008;21(1):56–64. doi: 10.1097/QCO.0b013e3282f3d999.
    1. Paz-Bailey G, Morales-Miranda S, Jacobson JO, Gupta SK, Sabin K, Mendoza S, Paredes M, Alvarez B, Monterroso E. High rates of STD and sexual risk behaviors among Garifunas in Honduras. J Acquir Immune Defic Syndr. 2009;51(Suppl 1):S26–34. doi: 10.1097/QAI.0b013e3181a2647b.
    1. Miller WC, Zenilman JM. Epidemiology of chlamydial infection, gonorrhea, and trichomoniasis in the United States--2005. Infect Dis Clin North Am. 2005;19(2):281–296. doi: 10.1016/j.idc.2005.04.001.
    1. Shafir SC, Sorvillo FJ, Smith L. Current issues and considerations regarding trichomoniasis and human immunodeficiency virus in African-Americans. Clin Microbiol Rev. 2009;22(1):37–45. doi: 10.1128/CMR.00002-08.
    1. Freeman AH, Katz KA, Pandori MW, Rauch LM, Kohn RP, Liska S, Bernstein KT, Klausner JD. Prevalence and correlates of Trichomonas vaginalis among incarcerated persons assessed using a highly sensitive molecular assay. Sex Transm Dis. 2010;37(3):165–168. doi: 10.1097/OLQ.0b013e3181bcd3fc.
    1. Rathod SD, Krupp K, Klausner JD, Arun A, Reingold AL, Madhivanan P. Bacterial vaginosis and risk for Trichomonas vaginalis infection: a longitudinal analysis. Sex Transm Dis. 2011;38(9):882–886. doi: 10.1097/OLQ.0b013e31821f91a1.
    1. Harp DF, Chowdhury I. Trichomoniasis: evaluation to execution. Eur J Obstet Gynecol Reprod Biol. 2011;157(1):3–9. doi: 10.1016/j.ejogrb.2011.02.024.
    1. Carlton JM, Hirt RP, Silva JC, Delcher AL, Schatz M, Zhao Q, Wortman JR, Bidwell SL, Alsmark UC, Besteiro S, et al. Draft genome sequence of the sexually transmitted pathogen Trichomonas vaginalis. Science. 2007;315(5809):207–212. doi: 10.1126/science.1132894.
    1. Petrin D, Delgaty K, Bhatt R, Garber G. Clinical and microbiological aspects of Trichomonas vaginalis. Clin Microbiol Rev. 1998;11(2):300–317.
    1. Krieger JN. Trichomoniasis in men: old issues and new data. Sex Transm Dis. 1995;22(2):83–96. doi: 10.1097/00007435-199503000-00003.
    1. Burch TA, Rees CW, Reardon L. Diagnosis of Trichomonas vaginalis vaginitis. Am J Obstet Gynecol. 1959;77(2):309–313. doi: 10.1016/0002-9378(59)90232-7.
    1. Afzan MY, Suresh K. Pseudocyst forms of Trichomonas vaginalis from cervical neoplasia. Parasitol Res. 2012;111(1):371–381. doi: 10.1007/s00436-012-2848-3.
    1. Pereira-Neves A, Ribeiro KC, Benchimol M. Pseudocysts in trichomonads--new insights. Protist. 2003;154(3–4):313–329. doi: 10.1078/143446103322454095.
    1. Charles SX. Epidemiology of trichomonas vaginalis (TV) in rural adolescent and juvenile children. J Trop Pediatr. 1991;37(2):90. doi: 10.1093/tropej/37.2.90.
    1. Adu-Sarkodie Y. Trichomonas vaginalis transmission in a family. Genitourin Med. 1995;71(3):199–200.
    1. Crucitti T, Jespers V, Mulenga C, Khondowe S, Vandepitte J, Buve A. Non-sexual transmission of Trichomonas vaginalis in adolescent girls attending school in Ndola, Zambia. PLoS One. 2011;6(1):e16310. doi: 10.1371/journal.pone.0016310.
    1. Goodman RP, Freret TS, Kula T, Geller AM, Talkington MW, Tang-Fernandez V, Suciu O, Demidenko AA, Ghabrial SA, Beach DH, et al. Clinical isolates of Trichomonas vaginalis concurrently infected by strains of up to four Trichomonasvirus species (Family Totiviridae) J Virol. 2011;85(9):4258–4270. doi: 10.1128/JVI.00220-11.
    1. Sena AC, Miller WC, Hobbs MM, Schwebke JR, Leone PA, Swygard H, Atashili J, Cohen MS. Trichomonas vaginalis infection in male sexual partners: implications for diagnosis, treatment, and prevention. Clin Infect Dis. 2007;44(1):13–22. doi: 10.1086/511144.
    1. Wolner-Hanssen P, Krieger JN, Stevens CE, Kiviat NB, Koutsky L, Critchlow C, DeRouen T, Hillier S, Holmes KK. Clinical manifestations of vaginal trichomoniasis. JAMA. 1989;261(4):571–576. doi: 10.1001/jama.1989.03420040109029.
    1. Martinez-Garcia F, Regadera J, Mayer R, Sanchez S, Nistal M. Protozoan infections in the male genital tract. J Urol. 1996;156(2 Pt 1):340–349. doi: 10.1097/00005392-199608000-00003.
    1. Allsworth JE, Ratner JA, Peipert JF. Trichomoniasis and other sexually transmitted infections: results from the 2001–2004 National Health and Nutrition Examination Surveys. Sex Transm Dis. 2009;36(12):738–744. doi: 10.1097/OLQ.0b013e3181b38a4b.
    1. Silver BJ, Guy RJ, Kaldor JM, Jamil MS, Rumbold AR. Trichomonas vaginalis as a cause of perinatal morbidity: a systematic review and meta-analysis. Sex Transm Dis. 2014;41(6):369–376. doi: 10.1097/OLQ.0000000000000134.
    1. Mann JR, McDermott S, Barnes TL, Hardin J, Bao H, Zhou L. Trichomoniasis in pregnancy and mental retardation in children. Ann Epidemiol. 2009;19(12):891–899. doi: 10.1016/j.annepidem.2009.08.004.
    1. Schwandt A, Williams C, Beigi RH. Perinatal transmission of Trichomonas vaginalis: a case report. J Reprod Med. 2008;53(1):59–61.
    1. Carter JE, Whithaus KC. Neonatal respiratory tract involvement by Trichomonas vaginalis: a case report and review of the literature. Am J Trop Med Hyg. 2008;78(1):17–19.
    1. Temesvari P, Kerekes A, Tege A, Szarka K. Demonstration of Trichomonas vaginalis in tracheal aspirates in infants with early respiratory failure. J Matern Fetal Neonatal Med. 2002;11(5):347–349. doi: 10.1080/jmf.11.5.347.349.
    1. Kissinger P, Adamski A. Trichomoniasis and HIV interactions: a review. Sex Transm Infect. 2013;89(6):426–433. doi: 10.1136/sextrans-2012-051005.
    1. Sardana S, Sodhani P, Agarwal SS, Sehgal A, Roy M, Singh V, Bhatnagar P, Murthy NS. Epidemiologic analysis of Trichomonas vaginalis infection in inflammatory smears. Acta Cytol. 1994;38(5):693–697.
    1. Guenthner PC, Secor WE, Dezzutti CS. Trichomonas vaginalis-induced epithelial monolayer disruption and human immunodeficiency virus type 1 (HIV-1) replication: implications for the sexual transmission of HIV-1. Infect Immun. 2005;73(7):4155–4160. doi: 10.1128/IAI.73.7.4155-4160.2005.
    1. Moodley P, Connolly C, Sturm AW. Interrelationships among human immunodeficiency virus type 1 infection, bacterial vaginosis, trichomoniasis, and the presence of yeasts. J Infect Dis. 2002;185(1):69–73. doi: 10.1086/338027.
    1. van de Wijgert JH, Morrison CS, Brown J, Kwok C, Van Der Pol B, Chipato T, Byamugisha JK, Padian N, Salata RA. Disentangling contributions of reproductive tract infections to HIV acquisition in African Women. Sex Transm Dis. 2009;36(6):357–364. doi: 10.1097/OLQ.0b013e3181a4f695.
    1. Sorvillo F, Kerndt P. Trichomonas vaginalis and amplification of HIV-1 transmission. Lancet. 1998;351(9097):213–214. doi: 10.1016/S0140-6736(05)78181-2.
    1. Chesson HW, Blandford JM, Pinkerton SD. Estimates of the annual number and cost of new HIV infections among women attributable to trichomoniasis in the United States. Sex Transm Dis. 2004;31(9):547–551. doi: 10.1097/01.olq.0000137900.63660.98.
    1. McClelland RS. Trichomonas vaginalis infection: can we afford to do nothing? J Infect Dis. 2008;197(4):487–489. doi: 10.1086/526498.
    1. Price MA, Stewart SR, Miller WC, Behets F, Dow WH, Martinson FE, Chilongozi D, Cohen MS. The cost-effectiveness of treating male trichomoniasis to avert HIV transmission in men seeking sexually transmitted disease care in Malawi. J Acquir Immune Defic Syndr. 2006;43(2):202–209. doi: 10.1097/01.qai.0000229014.39451.33.
    1. Sorvillo F, Smith L, Kerndt P, Ash L. Trichomonas vaginalis, HIV, and African-Americans. Emerg Infect Dis. 2001;7(6):927–932. doi: 10.3201/eid0706.010603.
    1. Price MA, Zimba D, Hoffman IF, Kaydos-Daniels SC, Miller WC, Martinson F, Chilongozi D, Kip E, Msowoya E, Hobbs MM, et al. Addition of treatment for trichomoniasis to syndromic management of urethritis in Malawi: a randomized clinical trial. Sex Transm Dis. 2003;30(6):516–522. doi: 10.1097/00007435-200306000-00009.
    1. Wang CC, McClelland RS, Reilly M, Overbaugh J, Emery SR, Mandaliya K, Chohan B, Ndinya-Achola J, Bwayo J, Kreiss JK. The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1. J Infect Dis. 2001;183(7):1017–1022. doi: 10.1086/319287.
    1. Kissinger P, Amedee A, Clark RA, Dumestre J, Theall KP, Myers L, Hagensee ME, Farley TA, Martin DH. Trichomonas vaginalis treatment reduces vaginal HIV-1 shedding. Sex Transm Dis. 2009;36(1):11–16. doi: 10.1097/OLQ.0b013e318186decf.
    1. Boselli F, Chiossi G, Bortolamasi M, Gallinelli A. Prevalence and determinants of genital shedding of herpes simplex virus among women attending Italian colposcopy clinics. Eur J Obstet Gynecol Reprod Biol. 2005;118(1):86–90. doi: 10.1016/j.ejogrb.2004.05.017.
    1. Gottlieb SL, Douglas JM, Jr, Foster M, Schmid DS, Newman DR, Baron AE, Bolan G, Iatesta M, Malotte CK, Zenilman J, et al. Incidence of herpes simplex virus type 2 infection in 5 sexually transmitted disease (STD) clinics and the effect of HIV/STD risk-reduction counseling. J Infect Dis. 2004;190(6):1059–1067. doi: 10.1086/423323.
    1. Zhang ZF, Begg CB. Is Trichomonas vaginalis a cause of cervical neoplasia? Results from a combined analysis of 24 studies. Int J Epidemiol. 1994;23(4):682–690. doi: 10.1093/ije/23.4.682.
    1. Viikki M, Pukkala E, Nieminen P, Hakama M. Gynaecological infections as risk determinants of subsequent cervical neoplasia. Acta Oncol. 2000;39(1):71–75. doi: 10.1080/028418600431003.
    1. Roeters AM, Boon ME, van Haaften M, Vernooij F, Bontekoe TR, Heintz AP. Inflammatory events as detected in cervical smears and squamous intraepithelial lesions. Diagn Cytopathol. 2010;38(2):85–93.
    1. Li CD, Zhang WY, Wu MH, Zhang SW, Zhou BL, Zhu L, Pan J, Wang JD. Analysis of high risk factors associated with cervical intraepithelial neoplasia in married women aged 25–54 years in Beijing between 2007–2008. Zhonghua Fu Chan Ke Za Zhi. 2010;45(10):757–761.
    1. Yap EH, Ho TH, Chan YC, Thong TW, Ng GC, Ho LC, Singh M. Serum antibodies to Trichomonas vaginalis in invasive cervical cancer patients. Genitourin Med. 1995;71(6):402–404.
    1. Sutcliffe S, Alderete JF, Till C, Goodman PJ, Hsing AW, Zenilman JM, De Marzo AM, Platz EA. Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer Prevention Trial. Int J Cancer. 2009;124(9):2082–2087. doi: 10.1002/ijc.24144.
    1. Sutcliffe S, Giovannucci E, Alderete JF, Chang TH, Gaydos CA, Zenilman JM, De Marzo AM, Willett WC, Platz EA. Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(5):939–945. doi: 10.1158/1055-9965.EPI-05-0781.
    1. Kingston MA, Bansal D, Carlin EM. ‘Shelf life’ of trichomonas vaginalis. Int J STD AIDS. 2003;14(1):28–29. doi: 10.1258/095646203321043228.
    1. Peterman TA, Tian LH, Metcalf CA, Malotte CK, Paul SM, Douglas JM, Jr, Group R-S. Persistent, undetected Trichomonas vaginalis infections? Clin Infect Dis. 2009;48(2):259–260. doi: 10.1086/595706.
    1. Gatski M, Mena L, Levison J, Clark RA, Henderson H, Schmidt N, Rosenthal SL, Martin DH, Kissinger P. Patient-delivered partner treatment and Trichomonas vaginalis repeat infection among human immunodeficiency virus-infected women. Sex Transm Dis. 2010;37(8):502–505.
    1. Nye MB, Schwebke JR, Body BA. Comparison of APTIMA Trichomonas vaginalis transcription-mediated amplification to wet mount microscopy, culture, and polymerase chain reaction for diagnosis of trichomoniasis in men and women. Am J Obstet Gynecol. 2009;200(2):188. doi: 10.1016/j.ajog.2008.10.005.
    1. Huppert JS, Biro F, Lan D, Mortensen JE, Reed J, Slap GB. Urinary symptoms in adolescent females: STI or UTI? J Adolesc Health. 2007;40(5):418–424. doi: 10.1016/j.jadohealth.2006.12.010.
    1. Andrea SB, Chapin KC. Comparison of Aptima Trichomonas vaginalis transcription-mediated amplification assay and BD affirm VPIII for detection of T. vaginalis in symptomatic women: performance parameters and epidemiological implications. J Clin Microbiol. 2011;49(3):866–869. doi: 10.1128/JCM.02367-10.
    1. Van Der Pol B, Kraft CS, Williams JA. Use of an adaptation of a commercially available PCR assay aimed at diagnosis of chlamydia and gonorrhea to detect Trichomonas vaginalis in urogenital specimens. J Clin Microbiol. 2006;44(2):366–373. doi: 10.1128/JCM.44.2.366-373.2006.
    1. Huppert JS, Mortensen JE, Reed JL, Kahn JA, Rich KD, Miller WC, Hobbs MM. Rapid antigen testing compares favorably with transcription-mediated amplification assay for the detection of Trichomonas vaginalis in young women. Clin Infect Dis. 2007;45(2):194–198. doi: 10.1086/518851.
    1. Van Der Pol B, Williams JA, Orr DP, Batteiger BE, Fortenberry JD. Prevalence, incidence, natural history, and response to treatment of Trichomonas vaginalis infection among adolescent women. J Infect Dis. 2005;192(12):2039–2044. doi: 10.1086/498217.
    1. Williams JA, Ofner S, Batteiger BE, Fortenberry JD, Van Der Pol B. Duration of polymerase chain reaction-detectable DNA after treatment of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis infections in women. Sex Transm Dis. 2014;41(3):215–219. doi: 10.1097/OLQ.0000000000000102.
    1. Wendel KA, Workowski KA. Trichomoniasis: challenges to appropriate management. Clin Infect Dis. 2007;44(Suppl 3):S123–129. doi: 10.1086/511425.
    1. Cudmore SL, Garber GE. Prevention or treatment: the benefits of Trichomonas vaginalis vaccine. J Infect Public Health. 2010;3(2):47–53. doi: 10.1016/j.jiph.2010.01.003.
    1. Burtin P, Taddio A, Ariburnu O, Einarson TR, Koren G. Safety of metronidazole in pregnancy: a meta-analysis. Am J Obstet Gynecol. 1995;172(2 Pt 1):525–529. doi: 10.1016/0002-9378(95)90567-7.
    1. Caro-Paton T, Carvajal A, Martin de Diego I, Martin-Arias LH, Alvarez Requejo A, Rodriguez Pinilla E. Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol. 1997;44(2):179–182. doi: 10.1046/j.1365-2125.1997.00660.x.
    1. Workowski KA, Berman S, Centers for Disease C, Prevention Sexually transmitted diseases treatment guidelines, 2010. MMWR Recommend Rep. 2010;59(RR-12):1–110.
    1. Helms DJ, Mosure DJ, Secor WE, Workowski KA. Management of trichomonas vaginalis in women with suspected metronidazole hypersensitivity. Am J Obstet Gynecol. 2008;198(4):370. doi: 10.1016/j.ajog.2007.10.795.
    1. Chen MY, Smith NA, Fox EF, Bingham JS, Barlow D. Acetarsol pessaries in the treatment of metronidazole resistant Trichomonas vaginalis. Int J STD AIDS. 1999;10(4):277–280. doi: 10.1258/0956462991913943.
    1. Muzny C, Barnes A, Mena L. Symptomatic Trichomonas vaginalis infection in the setting of severe nitroimidazole allergy: successful treatment with boric acid. Sex Health. 2012;9(4):389–391. doi: 10.1071/SH11114.
    1. Goldman LM, Upcroft JA, Workowski K, Rapkin A. Treatment of metronidazole-resistant Trichomonas vaginalis. Sex Health. 2009;6(4):345–347. doi: 10.1071/SH09064.
    1. Nyirjesy P, Gilbert J, Mulcahy LJ. Resistant trichomoniasis: successful treatment with combination therapy. Sex Transm Dis. 2011;38(10):962–963. doi: 10.1097/OLQ.0b013e31822037e4.
    1. Dan M, Sobel JD. Failure of nitazoxanide to cure trichomoniasis in three women. Sex Transm Dis. 2007;34(10):813–814.
    1. Mammen-Tobin A, Wilson JD. Management of metronidazole-resistant Trichomonas vaginalis--a new approach. Int J STD AIDS. 2005;16(7):488–490. doi: 10.1258/0956462054308422.
    1. Vieira Pde B, Giordani RB, Macedo AJ, Tasca T. Natural and synthetic compound anti-Trichomonas vaginalis: an update review. Parasitol Res. 2015;114(4):1249–1261. doi: 10.1007/s00436-015-4340-3.
    1. Kissinger P, Hogben M. Expedited partner treatment for sexually transmitted infections: an update. Curr Infect Dis Rep. 2011;13(2):188–195. doi: 10.1007/s11908-010-0159-3.
    1. Gatski M, Martin DH, Levison J, Mena L, Clark RA, Murphy M, Henderson H, Schmidt N, Kissinger P. The influence of bacterial vaginosis on the response to Trichomonas vaginalis treatment among HIV-infected women. Sex Transm Infect. 2011;87(3):205–208. doi: 10.1136/sti.2010.046441.
    1. Adamski A, Clark RA, Mena L, Henderson H, Levison J, Schmidt N, Gebrekristos HT, Martin DH, Kissinger P. The influence of ART on the treatment of Trichomonas vaginalis among HIV-infected women. Clin Infect Dis. 2014;59(6):883–887. doi: 10.1093/cid/ciu401.
    1. Balkus JE, Richardson BA, Mochache V, Chohan V, Chan JD, Masese L, Shafi J, Marrazzo J, Farquhar C, McClelland RS. A prospective cohort study comparing the effect of single-dose 2 g metronidazole on Trichomonas vaginalis infection in HIV-seropositive versus HIV-seronegative women. Sex Transm Dis. 2013;40(6):499–505. doi: 10.1097/OLQ.0b013e31828fce34.
    1. Lazenby GB, Unal ER, Andrews AL, Simpson K. Cost-effectiveness analysis of annual Trichomonas vaginalis screening and treatment in HIV-positive women to prevent HIV transmission. Sex Transm Dis. 2014;41(6):353–358. doi: 10.1097/OLQ.0000000000000008.
    1. Kissinger P, Secor WE, Leichliter JS, Clark RA, Schmidt N, Curtin E, Martin DH. Early repeated infections with Trichomonas vaginalis among HIV-positive and HIV-negative women. Clin Infect Dis. 2008;46(7):994–999. doi: 10.1086/529149.
    1. Krashin JW, Koumans EH, Bradshaw-Sydnor AC, Braxton JR, Evan Secor W, Sawyer MK, Markowitz LE. Trichomonas vaginalis prevalence, incidence, risk factors and antibiotic-resistance in an adolescent population. Sex Transm Dis. 2010;37(7):440–4.
    1. Kissinger P, Schmidt N, Mohammed H, Leichliter JS, Gift TL, Meadors B, Sanders C, Farley TA. Patient-delivered partner treatment for Trichomonas vaginalis infection: a randomized controlled trial. Sex Transm Dis. 2006;33(7):445–450. doi: 10.1097/01.olq.0000204511.84485.4c.
    1. Spence MR, Harwell TS, Davies MC, Smith JL. The minimum single oral metronidazole dose for treating trichomoniasis: a randomized, blinded study. Obstet Gynecol. 1997;89(5 Pt 1):699–703. doi: 10.1016/S0029-7844(97)81437-8.
    1. Forna F, Gulmezoglu AM. Interventions for treating trichomoniasis in women. Cochrane Database Syst Rev. 2003;2:CD000218.
    1. Csonka GW. Trichomonal vaginitis treated with one dose of metronidazole. Br J Vener Dis. 1971;47(6):456–458.
    1. Hager WD, Brown ST, Kraus SJ, Kleris GS, Perkins GJ, Henderson M. Metronidazole for vaginal trichomoniasis. Seven-day vs single-dose regimens. JAMA. 1980;244(11):1219–1220. doi: 10.1001/jama.1980.03310110029023.
    1. Schwebke JR, Barrientes FJ. Prevalence of Trichomonas vaginalis isolates with resistance to metronidazole and tinidazole. Antimicrob Agents Chemother. 2006;50(12):4209–4210. doi: 10.1128/AAC.00814-06.
    1. Perez S, Fernandez-Verdugo A, Perez F, Vazquez F. Prevalence of 5-nitroimidazole-resistant trichomonas vaginalis in Oviedo, Spain. Sex Transm Dis. 2001;28(2):115–116. doi: 10.1097/00007435-200102000-00010.
    1. Schmid G, Narcisi E, Mosure D, Secor WE, Higgins J, Moreno H. Prevalence of metronidazole-resistant Trichomonas vaginalis in a gynecology clinic. J Reprod Med. 2001;46(6):545–549.
    1. Magnus M, Clark R, Myers L, Farley T, Kissinger PJ. Trichomonas vaginalis among HIV-Infected women: are immune status or protease inhibitor use associated with subsequent T. vaginalis positivity? Sex Transm Dis. 2003;30(11):839–843. doi: 10.1097/01.OLQ.0000086609.95617.8D.
    1. Niccolai LM, Kopicko JJ, Kassie A, Petros H, Clark RA, Kissinger P. Incidence and predictors of reinfection with Trichomonas vaginalis in HIV-infected women. Sex Transm Dis. 2000;27(5):284–288. doi: 10.1097/00007435-200005000-00009.
    1. Lyng J, Christensen J. A double-blind study of the value of treatment with a single dose tinidazole of partners to females with trichomoniasis. Acta Obstet Gynecol Scand. 1981;60(2):199–201.
    1. Schwebke JR, Desmond RA. A randomized controlled trial of partner notification methods for prevention of trichomoniasis in women. Sex Transm Dis. 2010;37(6):392–396.
    1. Hirt RP, Sherrard J. Trichomonas vaginalis origins, molecular pathobiology and clinical considerations. Curr Opin Infect Dis. 2015;28(1):72–79. doi: 10.1097/QCO.0000000000000128.
    1. Martin DH, Zozaya M, Lillis RA, Myers L, Nsuami MJ, Ferris MJ. Unique vaginal microbiota that includes an unknown Mycoplasma-like organism is associated with Trichomonas vaginalis infection. J Infect Dis. 2013;207(12):1922–1931. doi: 10.1093/infdis/jit100.
    1. Kissinger P, Mena L, Levison J, Clark RA, Gatski M, Henderson H, Schmidt N, Rosenthal S, Myers L, Martin DH. A randomized treatment trial: single versus 7 day dose of metronidazole for the treatment of trichomonas vaginalis among hiv-infected women. J Acquir Immune Defic Syndr. 2011;55(5):565–571. doi: 10.1097/QAI.0b013e3181eda955.
    1. Warren D, Klein RS, Sobel J, Kieke B, Jr, Brown W, Schuman P, Anderson J, Cu-Uvin S, Mayer K, Jamieson DJ, et al. A multicenter study of bacterial vaginosis in women with or at risk for human immunodeficiency virus infection. Infect Dis Obstet Gynecol. 2001;9(3):133–141. doi: 10.1155/S1064744901000242.
    1. Plitt SS, Garfein RS, Gaydos CA, Strathdee SA, Sherman SG, Taha TE. Prevalence and correlates of chlamydia trachomatis, neisseria gonorrhoeae, trichomonas vaginalis infections, and bacterial vaginosis among a cohort of young injection drug users in Baltimore, Maryland. Sex Transm Dis. 2005;32(7):446–453. doi: 10.1097/01.olq.0000154567.21291.59.
    1. Taha TE, Hoover DR, Dallabetta GA, Kumwenda NI, Mtimavalye LA, Yang LP, Liomba GN, Broadhead RL, Chiphangwi JD, Miotti PG. Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. AIDS. 1998;12(13):1699–1706. doi: 10.1097/00002030-199813000-00019.
    1. Sewankambo N, Gray RH, Wawer MJ, Paxton L, McNaim D, Wabwire-Mangen F, Serwadda D, Li C, Kiwanuka N, Hillier SL, et al. HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis. Lancet. 1997;350(9077):546–550. doi: 10.1016/S0140-6736(97)01063-5.
    1. Thomason JL, Gelbart SM, Sobun JF, Schulien MB, Hamilton PR. Comparison of four methods to detect Trichomonas vaginalis. J Clin Microbiol. 1988;26(9):1869–1870.
    1. Franklin TL, Monif GR. Trichomonas vaginalis and bacterial vaginosis. Coexistence in vaginal wet mount preparations from pregnant women. J Reprod Med. 2000;45(2):131–134.
    1. Demirezen S, Kaya D, Beksac S. Cytologic findings in pap smears with Actinomyces-like organisms. Acta Cytol. 2005;49(3):257–261. doi: 10.1159/000326146.
    1. Heller DS, Maslyak S, Skurnick J. Is the presence of Trichomonas on a Pap smear associated with an increased incidence of bacterial vaginosis? J Low Genit Tract Dis. 2006;10(3):137–139. doi: 10.1097/00128360-200607000-00002.
    1. Fettweis JM, Serrano MG, Huang B, Brooks JP, Glascock AL, Sheth NU, Vaginal Microbiome C, Strauss JF, 3rd, Jefferson KK, Buck GA. An emerging mycoplasma associated with trichomoniasis, vaginal infection and disease. PLoS One. 2014;9(10):e110943. doi: 10.1371/journal.pone.0110943.
    1. Brotman RM, Bradford LL, Conrad M, Gajer P, Ault K, Peralta L, Forney LJ, Carlton JM, Abdo Z, Ravel J. Association between Trichomonas vaginalis and vaginal bacterial community composition among reproductive-age women. Sex Transm Dis. 2012;39(10):807–812. doi: 10.1097/OLQ.0b013e3182631c79.
    1. Hillier SL, Krohn MA, Nugent RP, Gibbs RS. Characteristics of three vaginal flora patterns assessed by gram stain among pregnant women. Vaginal Infections and Prematurity Study Group. Am J Obstet Gynecol. 1992;166(3):938–944. doi: 10.1016/0002-9378(92)91368-K.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir